PTPRC and neoplasm: More importantly, the percentage of CCL4-producing CD45-negative cells was elevated in the secondary 4T1 tumors treated with CBDCA and anti-PD-1 antibodies by ~2-folds (Figure 7E, p < 0.01 and Figure 4E), as well as the other two tumor models.